ID   HCC-3
AC   CVCL_0C57
AS   CVCL_0C55
SY   HCC.3; HCC3; AKH13
DR   cancercelllines; CVCL_0C57
DR   Cosmic; 1628384
DR   Cosmic; 2162535
DR   TOKU-E; 3990
DR   Wikidata; Q54749093
RX   PubMed=16809312;
RX   PubMed=18594539;
RX   PubMed=23887712;
RX   PubMed=31063779;
WW   Info; LCCL; -; https://lccl.zucmanlab.com/hcc/cellLines/HCC.3
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Unspecified (PubMed=31063779).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Miscellaneous: Direct author submission of STR profile from Rohr-Udilova N.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 12
ST   D18S51: 14,17
ST   D21S11: 29
ST   D3S1358: 17,18
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 14,15
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 7,13
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C49 ! MF-3
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-04-25; Version: 12
//
RX   PubMed=16809312; DOI=10.1128/JVI.00020-06; PMCID=PMC1489065;
RA   Metzl C., Mischek D., Salmons B., Gunzburg W.H., Renner M.,
RA   Portsmouth D.;
RT   "Tissue- and tumor-specific targeting of murine leukemia virus-based
RT   replication-competent retroviral vectors.";
RL   J. Virol. 80:7070-7078(2006).
//
RX   PubMed=18594539; DOI=10.1038/sj.bjc.6604440; PMCID=PMC2453035;
RA   Sagmeister S., Eisenbauer M., Pirker C., Mohr T., Holzmann K.,
RA   Zwickl H., Bichler C., Kandioler-Eckersberger D., Wrba F., Mikulits W.,
RA   Gerner C., Shehata M., Majdic O., Streubel B., Berger W., Micksche M.,
RA   Zatloukal K., Schulte-Hermann R., Grasl-Kraupp B.;
RT   "New cellular tools reveal complex epithelial-mesenchymal interactions
RT   in hepatocarcinogenesis.";
RL   Br. J. Cancer 99:151-159(2008).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//